Halper Sadeh LLC Urges DigitalBridge, Amicus, Dynavax Shareholders to Know Their Rights Halper Sadeh LLC is urging shareholders of DigitalBridge, Amicus, and Dynavax to discuss their legal rights and possible claims concerning recent acquisitions for potential federal law violations.

Halper Sadeh LLC Urges DigitalBridge, Amicus, Dynavax Shareholders to Know Their Rights #USA #New_York #Dynavax #DigitalBridge #Amicus

Acquisitions: #Nukkleus > #Tiltan; #Nvidia > #Groq; #PiceaRobotics > #iRobot; #ZenaTech > #SpiewakLandSurveyor + #HoltSurveying&Mapping + #CasadoDesign

Agreed Acquisitions: #Meta > #Manus; #Sanofi > #Dynavax; #ServiceNow > #Armis

Sanofi neemt Dynavax over en versterkt vaccinportfolio Key takeaways Sanofi heeft aangekondigd dat het van plan is Dynavax Technologies Corporation over te nemen voor 2,2 miljard dollar (zo’n 1,9 miljard euro). De transactie zal de positie van Sanofi op de markt voor vaccinatie van volwassenen versterken. Dat gebeurt door het zeer succesvolle hepatitis B-vaccin, Heplisav-B, van Dynavax en een veelbelovende kandidaat voor […]

Sanofi neemt Dynavax over en versterkt vaccinportfolio #Sanofi #Dynavax #vaccins #gezondheid #biotechnologie

Sanofi acquiert Dynavax et renforce son portefeuille de vaccins Principaux renseignements Sanofi a annoncé son intention d’acquérir Dynavax Technologies Corporation pour 2,2 milliards de dollars (environ 1,9 milliard d’euros). Cette transaction renforcera la position de Sanofi sur le marché de la vaccination des adultes. Elle permettra d’intégrer à son portefeuille existant le vaccin très efficace contre l’hépatite B, Heplisav-B, de Dynavax, ainsi qu’un candidat […]

Sanofi acquiert Dynavax et renforce son portefeuille de vaccins #Sanofi #Dynavax #Vaccins #Santé #Acquisition

Sanofi pushes ahead on adult vaccines with $2.2 billion Dynavax deal The deal will help Sanofi diversify as RFK Jr. targets childhood immunizations.

#Sanofi pushes ahead on adult vaccines with $2.2 billion #Dynavax deal

www.reuters.com/business/hea...

Sanofi Enters Agreement to Acquire Dynavax for Vaccine Expansion Sanofi has announced its acquisition of Dynavax Technologies, enhancing its adult immunization portfolio with a hepatitis B vaccine and a shingles candidate.

Sanofi Enters Agreement to Acquire Dynavax for Vaccine Expansion #USA #Emeryville #Sanofi #Dynavax #HEPLISAV-B

Dynavax Technologies to Showcase Innovations at the Upcoming Evercore Healthcare Conference Dynavax Technologies is set to participate in the 8th Annual Evercore Healthcare Conference, presenting its pioneering vaccine solutions.

Dynavax Technologies to Showcase Innovations at the Upcoming Evercore Healthcare Conference #USA #Emeryville #Dynavax #HEPLISAV-B #CpG_1018

Dynavax and Vaxart Join Forces on Oral COVID-19 Vaccine Development Dynavax Technologies collaborates with Vaxart to develop a novel oral COVID-19 vaccine, leveraging unique delivery methods and aiming to enhance public health accessibility.

Dynavax and Vaxart Join Forces on Oral COVID-19 Vaccine Development #None #Emeryville #COVID-19 #Dynavax #Vaxart

Dynavax Announces Third Quarter 2025 Results and New Share Repurchase Program Worth $100 Million Dynavax Technologies reports a significant rise in HEPLISAV-B revenues and unveils a new $100 million share repurchase program in Q3 2025.

Dynavax Announces Third Quarter 2025 Results and New Share Repurchase Program Worth $100 Million #United_States #Emeryville #Dynavax #HEPLISAV-B #Vaxart

Dynavax Showcases Promising Results for Z-1018 Shingles Vaccine Candidate at IDWeek 2025 Dynavax presents promising data for its shingles vaccine Z-1018 at IDWeek 2025, showcasing comparable efficacy to Shingrix and improved tolerability.

Dynavax Showcases Promising Results for Z-1018 Shingles Vaccine Candidate at IDWeek 2025 #United_States #Emeryville #Dynavax #Z-1018 #Shingrix

Dynavax Unveils Positive Phase 1/2 Results for Innovative Shingles Vaccine Z-1018 Dynavax Technologies has reported promising Phase 1/2 trial results for its shingles vaccine candidate Z-1018, showing robust immune responses and favorable tolerability compared to Shingrix.

Dynavax Unveils Positive Phase 1/2 Results for Innovative Shingles Vaccine Z-1018 #United_States #Dynavax #Emeryville,_California #Z-1018 #Shingrix

Dynavax Technologies Unveils Strong Q2 2025 Results with Record Revenues Dynavax Technologies has reported impressive financial results for Q2 2025, marked by record revenues from its HEPLISAV-B vaccine and promising clinical updates.

Dynavax Technologies Unveils Strong Q2 2025 Results with Record Revenues #United_States #Emeryville #Hepatitis_B #Dynavax #HEPLISAV-B

Dynavax Technologies Pushes for Support of Board Director Nominees Ahead of Important Annual Meeting Dynavax Technologies calls for stockholders to back its board nominees ahead of the June 11 meeting, emphasizing their value and expertise over competitors.

Dynavax Technologies Pushes for Support of Board Director Nominees Ahead of Important Annual Meeting #USA #Emeryville #Annual_Meeting #Dynavax #gold_proxy

ISS Supports Dynavax's Directors: A Sign of Stability in Governance and Strategy The leading independent proxy advisory firm ISS has recommended that Dynavax's stockholders vote for its four director nominees, emphasizing strategic continuity and board effectiveness.

ISS Supports Dynavax's Directors: A Sign of Stability in Governance and Strategy #USA #Emeryville #ISS #Proxy_Vote #Dynavax

Dynavax Highlights Strong Financial Performance While Encouraging Votes for Board Nominees Dynavax Technologies emphasizes its robust financial growth and strategic direction in a recent investor presentation, encouraging shareholder engagement.

Dynavax Highlights Strong Financial Performance While Encouraging Votes for Board Nominees #USA #Emeryville #Board_of_Directors #Dynavax #HEPLISAV-B

Dynavax Technologies Unveils Strong Q1 2025 Financial Results and Promising New Vaccine Initiatives Dynavax Technologies reports impressive Q1 2025 financials with significant growth in HEPLISAV-B revenue, alongside announcements of new vaccine development initiatives.

Dynavax Technologies Unveils Strong Q1 2025 Financial Results and Promising New Vaccine Initiatives #United_States #Emeryville #Vaccine_Development #Dynavax #HEPLISAV-B

Dynavax Survey Reveals Americans Lack Awareness on Hepatitis B Risks and Vaccine Benefits A recent survey by Dynavax reveals a concerning lack of awareness among Americans regarding the dangers of hepatitis B and the importance of vaccination. Public education is essential.

Dynavax Survey Reveals Americans Lack Awareness on Hepatitis B Risks and Vaccine Benefits #United_States #Vaccination #Emeryville #Hepatitis_B #Dynavax

Dynavax Technologies Announces Strategic Debt Refinancing and Stock Buyback Initiative Dynavax Technologies has initiated a refinancing of its convertible debt, enhancing its financial structure while repurchasing shares.

Dynavax Technologies Announces Strategic Debt Refinancing and Stock Buyback Initiative #USA #Convertible_Notes #Emeryville #stock_buyback #Dynavax

Vaccine manufacturers should hold their own summit and invite the FDA.

#vaccines #Pfizer #astrazeneca #bavariannordic #biontech #dynavax #fda

Dynavax Technologies Reports Promising Financials and Future Plans for 2025 Dynavax Technologies has reported strong financial results for 2024 and provided optimistic guidance for 2025, aiming to solidify its market position.

Dynavax Technologies Reports Promising Financials and Future Plans for 2025 #United_States #Emeryville #Dynavax #HEPLISAV-B #vaccines

Dynavax Technologies Reports Impressive Financial Performance and Growth Strategies for 2024 Dynavax Technologies has reported significant growth in its financial performance for 2024, including a 26% increase in HEPLISAV-B revenue, as well as promising clinical developments.

Dynavax Technologies Reports Impressive Financial Performance and Growth Strategies for 2024 #United_States #Emeryville #Dynavax #HEPLISAV-B #vaccine